SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $271.26 million. The enterprise value is $179.92 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 70.28 million shares outstanding. The number of shares has increased by 562.28% in one year.
| Current Share Class | 70.28M |
| Shares Outstanding | 70.28M |
| Shares Change (YoY) | +562.28% |
| Shares Change (QoQ) | -38.36% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 26.84% |
| Float | 48.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 42.22 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.46 |
| Quick Ratio | 9.13 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -203.41 |
Financial Efficiency
Return on equity (ROE) is 14.96% and return on invested capital (ROIC) is -32.53%.
| Return on Equity (ROE) | 14.96% |
| Return on Assets (ROA) | -28.20% |
| Return on Invested Capital (ROIC) | -32.53% |
| Return on Capital Employed (ROCE) | -30.19% |
| Weighted Average Cost of Capital (WACC) | 7.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $49,550 |
| Employee Count | 86 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +213.82% in the last 52 weeks. The beta is 0.61, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +213.82% |
| 50-Day Moving Average | 3.95 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 49.31 |
| Average Volume (20 Days) | 633,227 |
Short Selling Information
The latest short interest is 2.50 million, so 3.56% of the outstanding shares have been sold short.
| Short Interest | 2.50M |
| Short Previous Month | 1.95M |
| Short % of Shares Out | 3.56% |
| Short % of Float | 5.21% |
| Short Ratio (days to cover) | 3.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | -33.35M |
| Operating Income | -48.95M |
| Pretax Income | 13.27M |
| Net Income | 4.26M |
| EBITDA | -45.87M |
| EBIT | -48.95M |
| Earnings Per Share (EPS) | -$0.79 |
Full Income StatementBalance Sheet
The company has $96.59 million in cash and $5.95 million in debt, with a net cash position of $90.64 million or $1.29 per share.
| Cash & Cash Equivalents | 96.59M |
| Total Debt | 5.95M |
| Net Cash | 90.64M |
| Net Cash Per Share | $1.29 |
| Equity (Book Value) | 151.49M |
| Book Value Per Share | 3.18 |
| Working Capital | 90.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$44.78 million and capital expenditures -$933,156, giving a free cash flow of -$45.71 million.
| Operating Cash Flow | -44.78M |
| Capital Expenditures | -933,156 |
| Depreciation & Amortization | 3.08M |
| Net Borrowing | -418,412 |
| Free Cash Flow | -45.71M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -562.28% |
| Shareholder Yield | -562.28% |
| Earnings Yield | 1.57% |
| FCF Yield | -16.89% |
Analyst Forecast
The average price target for SABS is $10.75, which is 178.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.75 |
| Price Target Difference | 178.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
